Altimmune’s (ALT) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Altimmune (NASDAQ:ALT) in a research note released on Wednesday morning,Weiss Ratings reports.

ALT has been the subject of a number of other research reports. The Goldman Sachs Group raised shares of Altimmune to a “strong sell” rating in a research report on Thursday, July 10th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Wednesday, August 13th. UBS Group lowered their price objective on shares of Altimmune from $26.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. JMP Securities lowered their price objective on shares of Altimmune from $25.00 to $15.00 and set a “market outperform” rating for the company in a research report on Thursday, July 10th. Finally, Wall Street Zen raised shares of Altimmune from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Altimmune presently has a consensus rating of “Hold” and an average target price of $17.40.

Altimmune Stock Performance

Altimmune stock opened at $3.92 on Wednesday. The firm has a 50 day simple moving average of $3.72 and a 200-day simple moving average of $4.62. Altimmune has a 1-year low of $2.90 and a 1-year high of $11.16. The company has a debt-to-equity ratio of 0.09, a current ratio of 20.44 and a quick ratio of 20.44. The stock has a market cap of $345.98 million, a price-to-earnings ratio of -3.32 and a beta of 0.07.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. On average, analysts expect that Altimmune will post -1.35 EPS for the current year.

Institutional Investors Weigh In On Altimmune

A number of hedge funds and other institutional investors have recently modified their holdings of ALT. Federated Hermes Inc. raised its holdings in shares of Altimmune by 387.7% in the 2nd quarter. Federated Hermes Inc. now owns 915,458 shares of the company’s stock valued at $3,543,000 after purchasing an additional 727,731 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Altimmune by 155.2% in the 2nd quarter. Bank of America Corp DE now owns 716,019 shares of the company’s stock valued at $2,771,000 after purchasing an additional 435,467 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Altimmune in the 1st quarter valued at $1,304,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Altimmune by 25,474.2% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 239,630 shares of the company’s stock valued at $927,000 after purchasing an additional 238,693 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Altimmune by 13.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock valued at $7,489,000 after purchasing an additional 228,995 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.